Thank you to our speakers, sponsors, and delegates who joined us in London for the summit! If you are interested in the 2024 event, please get in touch:
Engineering Novel Allogeneic Candidates to Overcome Immunogenicity, Revolutionize Safety & Drive Durability to Accelerate Clinical Success & Scale Up Across Europe
The 3rd Allogeneic Cell Therapies Summit Europe
Building Scalable Universal Cell Therapies from Bench to Bedside
After a transformative year of IND approvals and exciting clinical data, there is a novel excitement in the off-the-shelf community. Industry experts joined to discuss the current landscape and promising emerging pipelines at the 3rd Allogeneic Cell Therapies Summit Europe!
There were expert insights from Caribou Biosciences, Adicet Bio, AdaptImmune and many more as they shared their recent breakthroughs and strategies to overcome challenges such as alloreactivity, durability, and upscaling their donor-derived therapies.
As 2024 ramps up to be the turning point for regenerative medicine, there has never been a better time to have connected and networked with industry leaders, solving shared challenges and making their allogeneic therapy a clinical success story.
What You Would Have Learned:
- Whether you report to the EMA, MHRA or FDA, our Regulatory Panel will answer your burning questions about regulations for universal cell therapies.
- Take home actionable strategies to improve the longevity of your allogeneic product, inspired by the talks held by Cellectis and Smart Immune.
- Take home learnings from across cell types, with talks discussing CAR-T, Natural Killer, Gamma Delta T, Dendritic Cells and more.